Recent developments in the management of secondary hyperparathyroidismGOODMAN, William G.Kidney international. 2001, Vol 59, Num 3, pp 1187-1201, issn 0085-2538Article

Calcimimetic agents and secondary hyperparathyroidism: rationale for use and results from clinical trialsGOODMAN, William G.Pediatric nephrology (Berlin, West). 2003, Vol 18, Num 12, pp 1206-1210, issn 0931-041X, 5 p.Article

Calcimimetic agents and secondary hyperparathyroidism: treatment and preventionGOODMAN, William G.Nephrology, dialysis, transplantation (Print). 2002, Vol 17, Num 2, pp 204-207, issn 0931-0509Article

Importance of hyperphosphataemia in the cardio-renal axisGOODMAN, William G.Nephrology, dialysis, transplantation (Print). 2004, Vol 19, pp i4-i8, issn 0931-0509, SUP1Conference Paper

New lessons from old assays: parathyroid hormone (PTH), its receptors, and the potential biological relevance of PTH fragmentsGOODMAN, William G; SALUSKY, Isidro B; JÜPPNER, Harald et al.Nephrology, dialysis, transplantation (Print). 2002, Vol 17, Num 10, pp 1731-1736, issn 0931-0509Article

Role of the calcium-sensing receptor in parathyroid gland physiologyCHEN, Randolph A; GOODMAN, William G.American journal of physiology. Renal physiology. 2004, Vol 55, Num 6, pp F1005-F1011, issn 1931-857XArticle

Vascular calcification in chronic kidney diseaseGOODMAN, William G; LONDON, Gerard.American journal of kidney diseases. 2004, Vol 43, Num 3, pp 572-579, issn 0272-6386, 8 p.Article

Cardiovascular calcification in end-stage renal diseaseSALUSKY, Isidro B; GOODMAN, William G.Nephrology, dialysis, transplantation (Print). 2002, Vol 17, Num 2, pp 336-339, issn 0931-0509Article

Assays for parathyroid hormone and their use in patients with end-stage renal diseaseGOODMAN, William G.Blood purification. 2003, Vol 21, Num 1, pp 118-123, issn 0253-5068, 6 p.Conference Paper

Adynamic renal osteodystrophy : Is there a problem?SALUSKY, Isidro B; GOODMAN, William G.Journal of the American Society of Nephrology. 2001, Vol 12, Num 9, pp 1978-1985, issn 1046-6673Article

Development and progression of secondary hyperparathyroidism in chronic kidney disease : lessons from molecular geneticsGOODMAN, William G; QUARLES, L. D.Kidney international. 2008, Vol 74, Num 3, pp 276-288, issn 0085-2538, 13 p.Article

Parathyroid hormone (PTH), PTH-derived peptides, and new PTH assays in renal osteodystrophyGOODMAN, William G; JÜPPNER, Harald; SALUSKY, Isidro B et al.Kidney international. 2003, Vol 63, Num 1, pp 1-11, issn 0085-2538, 11 p.Article

Bone density measurements in pediatric patients with renal osteodystrophyLIMA, Eleonora M; GOODMAN, William G; KUIZON, Beatriz D et al.Pediatric nephrology (Berlin, West). 2003, Vol 18, Num 6, pp 554-559, issn 0931-041X, 6 p.Article

Growth hormone and the skeleton in pediatric renal allograft recipientsSANCHEZ, Cheryl P; KUIZON, Beatriz D; GOODMAN, William G et al.Pediatric nephrology (Berlin, West). 2002, Vol 17, Num 5, pp 322-328, issn 0931-041XArticle

Efficacy and side effects of intermittent intravenous and oral doxercalciferol (1α-hydroxyvitamin D₂) in dialysis patients with secondary hyperparathyroidism : A sequential comparisonMAUNG, Hla M; ELANGOVAN, Loganathan; ROBERTSON, John A et al.American journal of kidney diseases. 2001, Vol 37, Num 3, pp 532-543, issn 0272-6386Article

Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HClMOE, Sharon M; CHERTOW, Glenn M; OLSON, Kurt A et al.Kidney international. 2005, Vol 67, Num 2, pp 760-771, issn 0085-2538, 12 p.Article

The calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidismGOODMAN, William G; HLADIK, Gerald A; TURNER, Stewart A et al.Journal of the American Society of Nephrology. 2002, Vol 13, Num 4, pp 1017-1024, issn 1046-6673Article

First- and second-generation immunometric PTH assays during treatment of hyperparathyroidism with cinacalcet HClMARTIN, Kevin J; JÜPPNER, Harald; GUO, Matthew D et al.Kidney international. 2005, Vol 68, Num 3, pp 1236-1243, issn 0085-2538, 8 p.Article

Sevelamer controls parathyroid hormone-induced bone disease as efficiently as calcium carbonate without increasing serum calcium levels during therapy with active vitamin D sterolsSALUSKY, Isidro B; GOODMAN, William G; SAHNEY, Shobha et al.Journal of the American Society of Nephrology. 2005, Vol 16, Num 8, pp 2501-2508, issn 1046-6673, 8 p.Article

The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidismLINDBERG, Jill S; MOE, Sharon M; GOODMAN, William G et al.Kidney international. 2003, Vol 63, Num 1, pp 248-254, issn 0085-2538, 7 p.Article

The effects of sevelamer and calcium acetate on proxies of atherosclerotic and arteriosclerotic vascular disease in hemodialysis patientsCHERTOW, Glenn M; RAGGI, Paolo; MCCARTHY, James T et al.American journal of nephrology. 2003, Vol 23, Num 5, pp 307-314, issn 0250-8095, 8 p.Article

Medical management of secondary hyperparathyroidism in chronic renal failureGOODMAN, William G.Nephrology, dialysis, transplantation (Print). 2003, Vol 18, pp iii2-iii8, issn 0931-0509, SUP3Conference Paper

Study design and subject baseline characteristics in the ADVANCE study: effects of cinacalcet on vascular calcification in haemodialysis patientsFLOEGE, Jürgen; RAGGI, Paolo; DOWNEY, Gerry et al.Nephrology, dialysis, transplantation (Print). 2010, Vol 25, Num 6, pp 1916-1923, issn 0931-0509, 8 p.Article

Specific measurement of PTH (1-84) in various forms of renal osteodystrophy (ROD) as assessed by bone histomorphometryLEHMANN, Gabriele; STEIN, Günter; HÜLLER, Manfr Ed et al.Kidney international. 2005, Vol 68, Num 3, pp 1206-1214, issn 0085-2538, 9 p.Article

Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysisBLOCK, Geoffrey A; MARTIN, Kevin J; COYNE, Daniel W et al.The New England journal of medicine. 2004, Vol 350, Num 15, pp 1516-1525, issn 0028-4793, 10 p.Article